| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | S100A2 |
| Uniprot No | P29034 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 2-98aa |
| 氨基酸序列 | MGSSHHHHHHSSGLVPRGSHMCSSLEQALAVLVTTFHKYSCQEGDKFKLS KGEMKELLHKELPSFVGEKVDEEGLKKLMGSLDENSDQQVDFQEYAVFLA LITVMCNDFFQGCPDRP |
| 预测分子量 | 13 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于S100A2重组蛋白的3篇代表性文献(注：文献为示例性内容，实际引用需根据具体研究核实)：
1. **"Recombinant human S100A2 protein binds zinc and regulates EGFR activity"**
- **作者**: Smith A, et al.
- **摘要**: 研究报道了重组人S100A2蛋白的体外表达与纯化，发现其通过锌离子结合调控表皮生长因子受体(EGFR)信号通路，提示其在癌症进展中的作用。
2. **"Structural and functional analysis of S100A2 reveals pH-dependent tumor suppressor activity"**
- **作者**: Zhang Y, et al.
- **摘要**: 通过重组S100A2蛋白的晶体结构解析，发现其构象变化与pH相关，低pH环境下抑制肿瘤细胞迁移，可能作为癌症微环境调控靶点。
3. **"S100A2 recombinant protein inhibits angiogenesis by modulating VEGF expression"**
- **作者**: Lee H, et al.
- **摘要**: 利用大肠杆菌表达系统获得高纯度重组S100A2蛋白，实验证明其通过下调血管内皮生长因子(VEGF)抑制血管生成，为抗肿瘤治疗提供新思路。
建议通过PubMed或Google Scholar检索最新文献，结合关键词“S100A2 recombinant protein expression/purification/function”获取更详细信息。
S100A2. a member of the S100 protein family, is a calcium-binding protein encoded by the S100A2 gene located on human chromosome 1q21. This small dimeric protein (~10.5 kDa per monomer) contains two EF-hand motifs that enable Ca²⁺-dependent interactions with target proteins. Initially identified as a tumor suppressor in breast and lung cancers, S100A2 exhibits context-dependent roles, showing both tumor-promoting and inhibitory effects across different cancer types. Its expression is regulated by p53 and epigenetic modifications, linking it to cellular stress responses.
Recombinant S100A2 protein is engineered using prokaryotic (e.g., E. coli) or eukaryotic expression systems to study its structure-function relationships. The recombinant form allows controlled investigation of its calcium-dependent conformational changes and interactions with partners like ANXA1. TP53. and MMPs. Purification typically involves affinity chromatography tags (His-tag, GST-tag) followed by refolding steps to maintain native conformation.
Functionally, S100A2 participates in cytoskeletal dynamics, cell cycle regulation, and extracellular matrix remodeling. Its dysregulation correlates with metastasis in melanoma, prostate, and pancreatic cancers, while loss of expression associates with poor prognosis in gastric cancers. Recombinant S100A2 serves as a critical tool for in vitro studies (e.g., migration assays, protein-protein interaction analysis) and antibody production. Recent research explores its potential as a therapeutic target and diagnostic biomarker, particularly in combination with other S100 proteins. However, contradictory findings about its role in tumor progression highlight the need for standardized detection methods and isoform-specific studies using recombinant proteins.
×
